Login to Your Account



FDA Issues CRL to Salix/ Progenics Constipation Drug

By Catherine Shaffer
Staff Writer

Tuesday, July 31, 2012
A day of anticipation ended in disappointment as Salix Pharmaceuticals Ltd. and Progenics Pharmaceuticals Inc. received a complete response letter late Friday from the FDA for injectable Relistor (methylnaltrexone bromide) for opioid-induced constipation in adult patients with chronic, noncancer pain, which has not responded to treatment with laxatives.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription